Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability. This adoption positions Hoth at the forefront of AI-driven drug development, reinforcing its commitment to cutting-edge innovation and accelerated therapeutic discovery. PredictBBB.ai, part of Lantern's RADR® AI platform, is a game-changing technology designed to eliminate one of the most significant bottlenecks in drug development: determining whether a candidate can cross the blood-brain barrier. By deploying this AI-driven solution, Hoth expects to streamline candidate selection, reduce development risk, and accelerate timelines toward transformative therapies. "At Lantern Pharma, we're very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its 94% accuracy in predicting blood-brain barrier permeability, is empowering researchers to make faster, smarter decisions, accelerating the path to life-changing therapies for patients worldwide." – Panna Sharma, CEO, Lantern Pharma. Lantern Pharma is a publicly traded company listed on the NASDAQ stock exchange. Strategic Impact for Hoth Therapeutics The ability to cross the blood-brain barrier is a critical success factor for drug candidates. With PredictBBB.ai, Hoth gains access to AI-powered insights that increase precision and reduce uncertainty, potentially creating faster regulatory pathways and higher value inflection points for its pipeline. "Hoth is committed to deploying disruptive technologies like AI to enhance precision in drug development," said Robb Knie, Chief Executive Officer Hoth Therapeutics. "Our integration of Lantern's PredictBBB.ai tool aligns with our mission to deliver life-changing therapies while driving efficiency, reducing costs, and unlocking new opportunities for patients and shareholders alike." About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ . Forward-Looking Statement This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. Investor Contact:LR Advisors LLC Email: [email protected]www.hoththerapeutics.comPhone: (678) 570-6791 SOURCE Hoth Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News